Kymab victorious before UK Supreme Court in Regeneron appeal
24-06-2020
Actavis v Eli Lilly: UK Supreme Court updates patent infringement test
12-07-2017
16-07-2020
Kerrick / iStockphoto.com
As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.
In a blow for Regeneron Pharmaceuticals, the UK Supreme Court has reversed a Court of Appeal decision by ruling that its patents relating to transgenic mice are invalid due to lack of “sufficiency”.
In 2001, Regeneron Pharmaceuticals filed patents for transgenic mice, which are used to produce antibodies for the treatment of humans. Thirteen years later the company sued Kymab when it produced its own genetically modified mice, for an infringement of its patents.
Kymab contested the validity of the patents, on the grounds of “insufficiency”. It is a requirement of UK patent law and of the European Patent Convention (EPC) that a patent application has to disclose an invention in a manner which is sufficiently clear and complete for it to be carried out by a person skilled in the art (article 83 of the EPC and section 14[3] of the Patents Act 1977).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Supreme Court, Regeneron, Kymab, Charles Russell Speechlys, applicants, principles, David Fyfield, ruling, Pharmaceuticals